Resources Management Corp CT ADV Takes $1.19 Million Position in Amgen Inc. $AMGN

Resources Management Corp CT ADV bought a new stake in shares of Amgen Inc. (NASDAQ:AMGN) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,637 shares of the medical research company’s stock, valued at approximately $1,190,000.

A number of other institutional investors have also recently modified their holdings of the stock. High Note Wealth LLC lifted its position in shares of Amgen by 5.8% during the 4th quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares during the period. TAGStone Capital Inc. lifted its position in shares of Amgen by 0.7% during the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock valued at $1,351,000 after acquiring an additional 28 shares during the period. Verus Capital Partners LLC lifted its position in shares of Amgen by 2.3% during the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock valued at $403,000 after acquiring an additional 28 shares during the period. Destination Wealth Management lifted its position in shares of Amgen by 2.1% during the 4th quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock valued at $456,000 after acquiring an additional 29 shares during the period. Finally, West Family Investments Inc. lifted its position in shares of Amgen by 1.1% during the 3rd quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock valued at $779,000 after acquiring an additional 30 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

Shares of AMGN stock opened at $355.20 on Monday. Amgen Inc. has a twelve month low of $267.83 and a twelve month high of $391.29. The stock’s fifty day simple moving average is $340.97 and its 200 day simple moving average is $345.80. The company has a quick ratio of 1.01, a current ratio of 1.26 and a debt-to-equity ratio of 5.65. The firm has a market capitalization of $191.70 billion, a P/E ratio of 24.72, a P/E/G ratio of 3.56 and a beta of 0.42.

Amgen (NASDAQ:AMGN) last posted its earnings results on Thursday, April 30th. The medical research company reported $5.15 EPS for the quarter, beating the consensus estimate of $4.77 by $0.38. The firm had revenue of $8.62 billion during the quarter, compared to the consensus estimate of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The business’s quarterly revenue was up 5.8% on a year-over-year basis. During the same period last year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. As a group, sell-side analysts predict that Amgen Inc. will post 22.38 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have recently commented on AMGN shares. Piper Sandler reissued an “overweight” rating on shares of Amgen in a report on Friday. Canaccord Genuity Group started coverage on Amgen in a report on Monday, April 20th. They set a “hold” rating and a $366.00 price target for the company. Truist Financial boosted their price target on Amgen from $325.00 to $327.00 and gave the stock a “hold” rating in a report on Friday, May 1st. Freedom Capital raised Amgen from a “hold” rating to a “strong-buy” rating in a report on Thursday, May 7th. Finally, The Goldman Sachs Group set a $389.00 price target on Amgen in a report on Friday, June 5th. Two investment analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $354.12.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the completion of the transaction, the senior vice president directly owned 7,009 shares in the company, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 0.85% of the company’s stock.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen said its phase 3 ABP 938 eye-disease study is advancing, with the drug aimed at challenging Regeneron’s Eylea HD in a major retina market. That keeps Amgen’s pipeline in focus as a potential future growth driver. Article Title
• Positive Sentiment: Amgen also highlighted its MARITIME-SWITCH phase 3 obesity trial, which is designed to capture GLP-1 switchers. Any success in obesity treatment could open another large market and improve long-term revenue expectations. Article Title
• Positive Sentiment: Some coverage pointed to Amgen as a value stock with supportive new data from the VESALIUS-CV cardiovascular study for Repatha, reinforcing confidence in the company’s broader portfolio. Article Title
• Neutral Sentiment: Amgen and outside analysts published bullish commentary on the stock’s valuation and earnings profile, but these were mostly opinion pieces rather than new business developments. Article Title
• Negative Sentiment: Investor sentiment is being pressured by reports that Amgen’s Tavneos faces a proposed FDA withdrawal, with the company seeking a hearing and commissioning an independent review to defend the drug’s data. Regulatory uncertainty around a $500 million product is a meaningful risk for the stock. Article Title
• Negative Sentiment: Reuters also reported that Amgen hired a research firm to reassess Tavneos data after FDA concerns, underscoring the regulatory overhang and near-term uncertainty for the drug. Article Title

Amgen Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.